Autoimmune Technologies (New Orleans, LA) is a privately-held biomedical company. It has licensed several breakthrough research discoveries from Tulane University School of Medicine and has made exciting discoveries of its own. Autoimmune is working to offer new diagnostic tests and new anti-viral therapeutics to the medical community based on this proprietary research. More information is available at www.autoimmune.com.
Corgenix and Autoimmune are members of the Viral Hemorrhagic Fever Consortium, working to develop state-of-the-art diagnostic products for biothreat agents and emerging pathogens.
AXA Diagnostics (Pomezia, Italy) is a private company that markets proprietary instrumentation and specialized diagnostic tests, with an emphasis on autoimmune in-vitro diagnostic products. AXA Diagnostics sells over 300 diagnostic products through a network of distributors in Europe and other international markets. AXA Diagnostics has obtained certification for the management of its quality system according to the requirements of UNI EN ISO 13485:2004. More information on AXA Diagnostics is available at www.axadiagnostics.com.
Corgenix and AXA work together on laboratory instrumentation. Corgenix distributes the SkyLab 752 system, which is manufactured by AXA.
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel biomarker-based molecular diagnostics to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and develops its diagnostic product candidates using its proprietary, versatile, and scalable technology platform, which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins and metabolites collected from bodily fluids. For more information about BG Medicine, see www.bg-medicine.com.
Corgenix manufactures the BG Medicine Galectin-3 ELISA product, an in-vitro diagnostic product used in conjunction with clinical evaluation to aid the assessment and prognosis of patients diagnosed with chronic heart failure.
Cayman Chemical Company, located in Ann Arbor, Michigan, helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis and other human health challenges. Cayman specializes in assay kits for measurement of hormones and biomarker, offering a broad range of specialty biochemicals used as research reagents and qualified standards.
Corgenix and Cayman partnered to develop a kit to measure urinary 11dhTxB2, a thromboxane metabolite to determine aspirin effect. Corgenix obtained FDA clearance in 2007, received a new CPT code in 2009 and increased CMS reimbursement in 2011 and commercialized the test kit known as AspirinWorks®/11dhTxB2.
For more information about AspirinWorks, go to www.aspirinworks.com.
diaDexus, Inc. (San Francisco, California) is focused on the development and commercialization of proprietary cardiovascular diagnostic products, addressing unmet needs in cardiovascular disease. The company’s PLAC ® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, respectively the #1 and #3 causes of death in the United States.
Corgenix, under the terms of a five-year agreement, will manufacture and supply the PLAC® Test ELISA product for diaDexus.
Dynex Technologies, Inc. (Chantilly, VA) was founded in 1952 and has been a leading innovator in microplate analysis, pipettors, dispensers, and dilutors for over fifty years. Today, Dynex designs and manufactures a full range of automated laboratory instruments and associated consumables that enable scientists and clinicians to make breakthrough discoveries and earlier, more-accurate diagnoses—innovations to improve health outcomes and enhance life. From fully-automated ELISA instruments and the latest in analysis and control software, Dynex designs products to meet the rigorous demands of the most challenging applications. More information is available at www.dynextechnologies.com
Corgenix distributes several Dynex instruments in the US, including the DSX® Four-Plate Automated ELISA Processing System and the DS2® Two-Plate Automated ELISA Processing System.
The ELITech Group (ELITech) is a major player in the international medical market. ELITech has brought together IVD specialty companies to provide the best offering of innovative, unique and also routine products to laboratories operating closer to the patient. It is comprised of Vital Scientific and Seppim (clinical chemistry analyzers and reagents), ELITech Microbio (microbiology kits), Wescor (unique laboratory instruments), inoDiag (unique multiplex serology devices), Nanogen (leading edge technology molecular biology kits), and SERFIB (microbiology and immunology kits). Through direct sales in Europe and North America and distribution capabilities in over 100 countries, the ELITech Group offers clinical chemistry, microbiology, immunology, and molecular biology products from its own facilities as well as complementary third-party products. More information is available at www.elitechgroup.com.
Corgenix and ELITech collaborate on product development and product sales. ELITech is the exclusive master distributor for commercializing Corgenix products outside of North America.
Nanōmix (Emeryville, CA) is a leading nanoelectronic detection company. It develops point-of-care devices based on its proprietary Sensation™ technology—the first universal detection platform offering unprecedented sensitivity that provides central lab-quality performance at the site of patient care. With more than 20 issued and pending patents and numerous awards that recognize its innovative technology, today Nanōmix is poised to become the premier provider of analytical detection devices for the next generation of rapid point-of-care (POC) diagnostics. Nanōmix was founded in 2000 as a Berkeley Lab spinout to commercialize proprietary nanotechnology for detecting a wide variety of biological molecules and gases for disease management, industrial process control, and the detection of pollutants in air and water. More information is available at http://www.nano.com.
Corgenix and Nanōmix are collaborating on adapting some of the Corgenix assays to the Nanōmix carbon nanotube (CNT) technology.
Randox (UK) is an international diagnostics company. Currently the twenty-third largest diagnostics company in the world, Randox develops, manufactures, and markets clinical diagnostic products worldwide. Their core products are Biochip Array Technology, clinical chemistry analyzers and reagents, quality controls and external quality assurance programs, environmental diagnostics, and recombinant proteins and antibodies. More information is available at www.randox.com.
Corgenix and Randox are collaborating on the application of some of the Corgenix products to Randox delivery platforms.
The Scripps Research Institute is one of the world’s largest independent, non-profit biomedical research organizations, and is at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Scripps Research is headquartered in La Jolla, California with a second campus located in Jupiter, Florida. Research at Scripps Florida focuses on basic biomedical science, drug discovery, and technology development. More information available at www.scripps.org
Corgenix and TSRI are members of the Viral Hemorrhagic Fever Consortium, working to develop state-of-the-art diagnostic products for biothreat agents and emerging pathogens.
Tulane University (New Orleans, LA) was founded in 1834. Tulane is one of the most highly regarded and selective research universities in the United States and is a member of the prestigious Association of American Universities. Tulane’s schools and colleges offer undergraduate, graduate, and professional degrees in the liberal arts, science and engineering, architecture, business, law, social work, medicine and public health, and tropical medicine. More information is available at www.tulane.edu.
Corgenix and Tulane are members of the Viral Hemorrhagic Fever Consortium, working to develop state-of-the-art diagnostic products for biothreat agents and emerging pathogens.
Vybion (Ithaca, NY) is a development-stage biotechnology company with a proprietary biopharmaceutical drug pipeline and platform technology for human monoclonal antibody-like molecule selection and affinity maturation, called ProCode. The company’s contract division has developed over 150 recombinant proteins in multiple expression systems, including 12 biologic drugs in various phases of clinical development. ProCode is being used commercially for Diagnostic and Biomarker product development with a rapid timeline of 10-12 weeks from target to affinity-matured, highly stable products. It has been used successfully where other technologies have failed; ProCode antibody molecules can be rapidly engineered for multiple platform formats and readouts. ProCode has also been used to develop a therapeutic product for Huntington’s disease that targets the cause of Huntington’s can prevent the progression of neuropathology. More information is available at www.vybion.com.
Corgenix and Vybion are members of the Viral Hemorrhagic Fever Consortium, working to develop state-of-the-art diagnostic products for biothreat agents and emerging pathogens.
Zalgen Labs (New Orleans, LA) is a recently-established biotechnology company dedicated to developing next-generation immunodiagnostic reagent systems, immunotherapeutics, and vaccine platforms for neglected viral diseases with global health and biodefense relevance. The company is devoted to product development and commercialization of leading candidate molecules emerging from Tulane University’s Viral Hemorrhagic Fever research program.
Corgenix and Zalgen members of the Viral Hemorrhagic Fever Consortium, working to develop state-of-the-art diagnostic products for biothreat agents and emerging pathogens.